Paediatric and adolescent infections

Lead Research Organisation: University College London

Abstract

Infections are a very important reason why children get sick. In many parts of the world, large numbers of children still die from infectious diseases, like HIV, tuberculosis, malaria and blood infections. This programme of research uses different kinds of studies to answer questions about how we can best manage and treat infections in children and young people, both to reduce their chance of dying and being sick for longer, but also to increase their quality of life. This includes studies to work out what are the best drugs to use, thinking not just about controlling infections like HIV or curing infections like tuberculosis, but also what side-effects the drugs might have or how easy or hard families find it to take different numbers and types of pills every day. Other studies are working out what aspects of living with a long-term infection like HIV have the biggest impact on children and young people’s lives, including how they manage school and friends. The goal is to provide evidence so that national and international guidelines for managing children and young people with infections recommend the best options for them.

Technical Summary

This integrated programme of complementary randomised trials, cohorts and pharmacovigilance studies aims to address questions about medicines and other interventions relevant to the most frequent and serious infectious diseases affecting children worldwide, in particular HIV, tuberculosis, malaria and sepsis. This is important because infectious diseases still dominate as causes of childhood mortality and morbidity and disproportionately affect children in sub-Saharan Africa. The programme has a large international component in Europe, North and South America, Thailand and Africa, and is at the forefront of both national and international research in paediatric infectious diseases.
The most appropriate research study designs are used for each specific question, not repeating all studies done in adults but using research in adults to identify where questions may be different or likely have different answers in children. Recognising the relative paucity of research in children, multiple complementary questions are addressed in factorial trials wherever possible to increase the evidence base for clinical management, and add value to the original investment in setting up and running the trial. Substudies investigating aspects such as pharmacokinetics, immunology, virology, and adherence are also included alongside trials wherever possible, as are additional analyses of trial data in an observational framework. High quality additional long-term data can also be collected in trial extensions by linking to cohorts. However, not all questions regarding the optimal management and treatment of HIV-infected children can be answered by randomised trials, because many cannot be framed as an implementable intervention. Data from cohort studies are used to answer these population-level questions of major relevance to children, adolescents and their families.
Our future plans are
• to continue to address clinically relevant questions in paediatric infectious diseases through appropriate research designs, and
• to ensure that results are incorporated into national and international management guidelines and policy, and then into clinical practice, including through additional operational research if relevant.
Several randomised trials in HIV and tuberculosis are funded and in advanced planning phases. Ongoing analyses within cohorts and cohort collaborations led by the group are addressing a wide range of contextual topics that can be generalised to the treatment and care of the wider population of HIV-infected children and young people. A large programme of pharmacovigilance studies continues to provide important long-term safety data to the European Medicines Agency on newly licensed antiretroviral drugs for children.

Publications

10 25 50

publication icon
Bienczak A (2016) Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. in Journal of acquired immune deficiency syndromes (1999)

publication icon
Bienczak A (2016) The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. in British journal of clinical pharmacology

 
Guideline Title Guidelines for the use of antiretroviral agents in pediatric HIV infection
Description Citation in NIH paediatric HIV guidelines, 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
URL https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0
 
Guideline Title WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children
Description Influence on WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact The new WHO guidelines recommend that rapid fluid resuscitation is not used for children with 1 or 2 signs of shock, following the results of the FEAST trial. However, they still recommend (more conservative) fluid resuscitation for children with all three signs of shock. FEAST found that rapid fluid resuscitation was associated with excess mortality for children with any definition of shock. The new guidelines are progress, but do not completely accord with the FEAST recommendations.
URL http://apps.who.int/iris/bitstream/10665/204463/1/9789241510219_eng.pdf?ua=1
 
Description Lablite training handbook adopted by Ugandan Ministry of Health
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Member of CIPHER Steering Committee
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Member, Paediatric/ Obstetric Subgroup of the HIV Clinical Reference Group, NHS
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Guideline Title Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: Interim guidance. Annex 3
Description ODYSSEY Pharmacokinetics data influences WHO paediatric dosing guidelines
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
URL https://www.who.int/hiv/pub/guidelines/ARV_Guidelines-2018-Annex3.pdf?ua=1
 
Guideline Title Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
Description Surviving sepsis guidelines
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Leaders in the paediatric field have now indicated maintenance fluid only in resource limited setting, where ICU care is not possible
URL https://www.ncbi.nlm.nih.gov/pubmed/32032264
 
Description WHO: Programmatic Management of Latent TB Infection
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description A randomized controlled trial of shorter course treatment for uncomplicated minimal childhood tuberculosis (SHINE)
Amount £3,217,996 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2014 
End 10/2018
 
Description Adolescents and Adults Living with Perinatal HIV cohort (AALPHI)/ Monument Trust (Sainsbury Family)
Amount £850,000 (GBP)
Organisation The Sainsbury Family Charitable Trusts 
Department Monument Trust
Sector Charity/Non Profit
Country United Kingdom
Start 08/2011 
End 12/2015
 
Description CIPHER Cohort Collaborative Projects ($ 142964; 2014 - 2015)
Amount $46,842 (USD)
Organisation International AIDS Society (IAS) 
Sector Charity/Non Profit
Country Switzerland
Start 01/2016 
End 12/2018
 
Description Collaborative Award (Severe Malaria Africa - A consortium for Research and Trials (SMAART))
Amount £3,944,185 (GBP)
Funding ID 209265 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2018 
End 06/2023
 
Description Collaborative HIV Paediatric Study (CHIPS)
Amount £870,000 (GBP)
Organisation NHS England 
Sector Public
Country United Kingdom
Start 04/2010 
End 03/2020
 
Description EU H2020 REACH
Amount £2,600,000 (GBP)
Organisation European Union 
Sector Public
Country European Union (EU)
Start 01/2019 
End 12/2020
 
Description HCVAVERT: designing a trial to cure hepatitis C virus (HCV) in HCV-infected pregnant women And prevent VERTical HCV transmission
Amount £148,437 (GBP)
Funding ID MR/R019746/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2018 
End 12/2019
 
Description Health Protection Research Unit, Blood Borne and Sexually Transmitted Infections
Amount £3,711,258 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2014 
 
Description IAS CIPHER
Amount £294,366 (GBP)
Organisation International AIDS Society (IAS) 
Sector Charity/Non Profit
Country Switzerland
Start 06/2018 
End 12/2019
 
Description Joint Global Health Trial Development Grant (TABS)
Amount £158,075 (GBP)
Funding ID MR/P021492/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2019
 
Description Joint Global Health Trials (H-PRIME trial)
Amount £4,375,063 (GBP)
Funding ID MR/P74363/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2020 
End 06/2025
 
Description MRC Training Fellowship - Felicity Fitzgerald
Amount £205,907 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2013 
End 09/2016
 
Description NHS England - CHIPS
Amount £150,000 (GBP)
Organisation NHS England 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2019
 
Description ODYSSEY qualitative substudy - how does moving to second line HIV treatment affect young people's treatment engagement - additional funding
Amount £47,678 (GBP)
Organisation Viiv Healthcare 
Sector Private
Country United Kingdom
Start 11/2019 
End 09/2020
 
Description ODYSSEY substudy: Folate and vitamin B12 status among children and adolescents in the ODYSSEY trial
Amount £32,476 (GBP)
Organisation Viiv Healthcare 
Sector Private
Country United Kingdom
Start 06/2019 
End 05/2020
 
Description PENTA Foundation, EPPICC grant
Amount £1,618,051 (GBP)
Organisation PENTA Foundation 
Sector Academic/University
Country France
Start 01/2016 
End 12/2020
 
Description Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial
Amount £3,986,746 (GBP)
Funding ID MC_EX_G1100693 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2012 
End 03/2018
 
Description SURE+DP: Improving Diagnosis and Prognosis for paediatric tuberculous meningitis through the SURE treatment trial
Amount £249,917 (GBP)
Organisation Meningitis Now 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2020 
End 07/2023
 
Description Severe Malaria Africa - A consortium for Research and Trials (SMAART)
Amount £4,028,013 (GBP)
Funding ID 209265/Z/17/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2019 
End 06/2023
 
Description TB CHAMP: Tuberculosis Child Multidrug-resistant Preventive Therapy Trial
Amount £463,638 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2016 
End 03/2019
 
Description ViiV PENTA (20) ODYSSEY additional funding
Amount £1,549,242 (GBP)
Organisation Viiv Healthcare 
Sector Private
Country United Kingdom
Start 08/2019 
End 06/2022
 
Description ViiV: investigator sponsored study
Amount £6,614,624 (GBP)
Organisation Viiv Healthcare 
Sector Private
Country United Kingdom
Start 03/2016 
End 05/2021
 
Description Wellcome Trust Collaborative Award in Science
Amount £3,944,185 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2019 
End 06/2024
 
Description Wellcome Trust Fellowship Helen Payne (Immunology substudies in CHER Trial)
Amount £314,606 (GBP)
Funding ID 095182/Z/10/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 07/2015
 
Description Wellcome Trust Fellowship Julia Kenny (CHAPAS 3 Trial & Substudies)
Amount £371,694 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2012 
End 07/2016
 
Title AALPHI database 
Description The AALPHI database contains clinical, neurocognitive and psychsocial data on 300 vertically HIV-infected young people and a comparison group of 100 HIV negative controls in the UK. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact Recruitment is in progress. This work is expected to significantly contribute to the evidence base on how to treat young people with vertical HIV in the future. 
 
Title CHIPS database 
Description Establishment of collaborative database containing clinical data on HIV-infected children in the UK/Ireland 
Type Of Material Database/Collection of data 
Provided To Others? Yes  
Impact Many publications written by us, and by collaborators, over the years - see URL below. Citations in international clinical guidelines. 
URL http://www.chipscohort.ac.uk/default.asp
 
Title CIPHER database 
Description Establishment of collaborative database containing clinical data on HIV-infected children in globally, representing all regions 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? Yes  
Impact Under development 
 
Title EPPICC database 
Description Establishment of collaborative database containing clinical data on HIV-infected children in Europe 
Type Of Material Database/Collection of data 
Year Produced 2011 
Provided To Others? Yes  
Impact Development of database has resulted in collaborative research projects and publications, both within the EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration) group, and in collaboration with other cohort collaborations, such as COHERE and EuroCoord. 
URL http://penta-id.org/hiv/eppicc-studies.html
 
Description CAPIT: University of Antwerp 
Organisation University of Antwerp
Country Belgium 
Sector Academic/University 
PI Contribution There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with Antwerp and their molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens.
Collaborator Contribution Still ongoing
Impact No outputs yet
Start Year 2019
 
Description CAPIT: University of Antwerp 
Organisation University of Antwerp
Country Belgium 
Sector Academic/University 
PI Contribution There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with an internationally recognised molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens.
Collaborator Contribution There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with an internationally recognised molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens.
Impact No output yet.
Start Year 2019
 
Description EPPICC (European Paediatric and Pregnancy HIV Cohort Collaboration) 
Organisation University of Padova
Country Italy 
Sector Academic/University 
PI Contribution We co-lead this network of paediatric observational HIV cohorts along with the Institute for Child Health. We have co-written the strategic plan for this network for the next 5 year period and have contributed to the EuroCoord bid which has secured funding for this network for the next 5 years.
Collaborator Contribution We are leading a new collaborative project (EPPICC infants) for this network, and the network has provided us with data to make the project feasible. The network also contributes epidemiological and clinical expertise to the project.
Impact Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009,23:597-604. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Fosamprenavir use in children in the European Union. A report to the European Medicines Agency (EMA), August 2009 (and repeated August 2010). London: MRC Clinical Trials Unit. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS. 2011;25:2279-2287.
Start Year 2007
 
Description Eldoret, Kenya 
Organisation Moi University
Country Kenya 
Sector Academic/University 
PI Contribution MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis.
Collaborator Contribution The Eldoret site are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients.
Impact Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including EARNEST and REALITY trials. Publications reporting the results of these trials which have influenced national, regional and international guidelines.
Start Year 2010
 
Description EuroCoord 
Organisation European Commission
Country European Union (EU) 
Sector Public 
PI Contribution scientific lead in writing project proposal; major partner. running paediatric PENTA trials and coordinating EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration).
Collaborator Contribution scientific coordinator 2011-2012 (Work Package 3). data harmonisation
Impact The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infectious Diseases. April: 2011, 273-283.
Start Year 2011
 
Description Gilead 
Organisation Gilead Sciences, Inc.
Department Gilead
Country United Kingdom 
Sector Private 
PI Contribution Design and conduct of trial protocol
Collaborator Contribution Review of protocol; provision of free drug
Impact Final protocol; fpfv planned Q2 2016; clinical, virology, immunology, pharmacokinetics
Start Year 2015
 
Description Gilead Sciences 
Organisation Gilead Sciences, Inc.
Department Gilead
Country United Kingdom 
Sector Private 
PI Contribution The research team ran the trial: Gilead contributed drugs and funding for specific substudies.
Collaborator Contribution Provided drugs for the trial
Impact Gilead provided first-line drugs for the trial, without which there would have been no publications. They also provided specific funding for PMID 18444867, 18839777 and for the current PENTA 17 (SMILE) elvitegravir trial
 
Description Harvard University 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration.
Collaborator Contribution Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration.
Impact Outputs are being generated and are forthcoming.
Start Year 2014
 
Description IAS 
Organisation International AIDS Society (IAS)
Country Switzerland 
Sector Charity/Non Profit 
PI Contribution Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study.
Collaborator Contribution Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study.
Impact Outputs forthcoming
Start Year 2014
 
Description INSERMSC10- US019.Essais thérapeutiques et maladies infectieuses 
Organisation National Institute of Health and Medical Research (INSERM)
Department INSERM SC10 - US019
Country France 
Sector Public 
PI Contribution Collaboration on management and co-ordination of PENTA trials
Collaborator Contribution Collaboration on management and co-ordination of PENTA trials
Impact All PENTA trials
 
Description Institute of Child Health 
Organisation University College London
Department Institute of Child Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborators on an MRC Immunology substudy within ARROW, delegating activities as described under an agreement with ICH, and we take responsibility for the project in accordance with the provisions of the Funder; application for NIHR funding for PENTA 16 immunology substudy
Collaborator Contribution Training, laboratory capacity building, teaching on PENTA Courses in East and West Europe and across Africa; sharing supervision of PhD Wellcome Trust studentships (Prof. Nigel Klein). Working together on EuroCoord, EPPICC, PENTA and Hepatitis C activities (Dr Claire Thorne). Collaborators and grant holders on NIHR PENTA 16 main study and biomarker substudy
Impact MRC grant secured in 2010. Work ongoing with baseline data presented at international conferences. Involves collaboration, training and capacity building between clinical, laboratory and trial management personnel at Ugandan and Zimbabwean sites and MRC CTU and Institute of Child Health. Site laboratory trained in four colour Immunophenotyping, nucleic acid extraction protocols and quantitative and real time PCRs (on HIV, CMV and EBV), and ELISA assays. Further training will be done on other techniques, in year 2 of the study. Training was done by personnel from both CTU and ICH.
Start Year 2010
 
Description JCRC, Uganda 
Organisation Joint Clinical Research Center, Kampala
Country Uganda 
Sector Academic/University 
PI Contribution MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis.
Collaborator Contribution JCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade.
Impact Multidiscplinary, including clinical medicine, statistics, trial management, laboratory management. Multiple clinical trial grants, including DART, ARROW, CHAPAS-3, EARNEST and REALITY trials. Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines.
 
Description Janssen Pharmaceutica 
Organisation Johnson & Johnson
Department Janssen Pharmaceutica
Country Global 
Sector Private 
PI Contribution We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency.
Collaborator Contribution We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency.
Impact European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. Antiviral Therapy, in press
Start Year 2011
 
Description KEMRI, Kilifi 
Organisation Kenyan Institute for Medical Research (KEMRI)
Country Kenya 
Sector Public 
PI Contribution MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis
Collaborator Contribution KEMRI are collaborating on the REALITY trial in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients.
Impact Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. REALITY clinical trial grant.
Start Year 2012
 
Description Kalawati Saran Children's Hospital (Lady Hardinge Hospital - LHH), Delhi 
Organisation Kalawati Saran Children's Hospital
Country India 
Sector Public 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description MLW, Malawi 
Organisation Wellcome Trust
Department Malawi-Liverpool Wellcome Trust Clinical Research Programme
Country Malawi 
Sector Academic/University 
PI Contribution MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis
Collaborator Contribution MLW are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site.
Impact Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including EARNEST and REALITY trials. Publications reporting the results of these trials which have influenced national, regional and international guidelines.
Start Year 2010
 
Description Makerere University - Johns Hopkins University (MU-JHU), Kampala 
Organisation Makerere University
Country Uganda 
Sector Academic/University 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description Monument Trust 
Organisation The Sainsbury Family Charitable Trusts
Department Monument Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution MRC CTU co-ordinates the CHAPAS-2 trial and the AALPHI study
Collaborator Contribution funding. The Monument Trust also contribute to I-Base publications which CTU staff have input in to.
Impact The Monument Trust funds the pharmacokinetic teams at 2 of the Ugandan trial centres for ARROW and CHAPAS trials. Some second-line children from ARROW are co-enroled in CHAPAS-2. AALPHI study started recruiting in Q3 2012.
Start Year 2010
 
Description National Institute of Health 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Provide scientific input in to all aspects of desgin, analysis and write up of the CHER trial (Prof Diana Gibb and Prof Abdul Babiker). With Prof Lynne Mofenson at NIAID we have worked on PENPACT-1 trial and cohort collaborations (HPPMCS).
Collaborator Contribution We have collaborated with NIH who funded the CHER trial in South Africa through a CIPRA grant. NIH have contributed funding and collaboration on the PENPACT-1 trial
Impact Papers from the CHER trial and PENPACT-1 trial, papers from HPPMCS.
 
Description National Lung Hospital, Hanoi 
Organisation Hanoi Lung Hospital
Country Viet Nam 
Sector Hospitals 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description OXFORD UNIVERSITY CLINICAL TRIALS UNIT (OUCRU) Vietnam 
Organisation University of Oxford
Department Oxford University Clinical Research Unit Vietnam (OUCRU)
Country Viet Nam 
Sector Academic/University 
PI Contribution Co-coordinating trial unit for the SURE study
Collaborator Contribution Co-coordinating trial unit for the SURE study
Impact Co-coordinating trial unit for the SURE study
Start Year 2019
 
Description Ph?m Ng?c Th?ch hospital, Ho Chi Minh City 
Organisation Pham Ngoc Thach Hospital
Country Viet Nam 
Sector Hospitals 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description Post Graduate Institute of Education and Medical Research (PGI), Chandigarh 
Organisation Institute of Post Graduate Medical Education And Research
Country India 
Sector Academic/University 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description Radboud University Nijmegen Medical Centre, the Netherlands 
Organisation Radboud University Nijmegen Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution The research team at the MRC co-ordinates the ARROW, CHAPAS-1,2,3 and PENTA trials and provides scientific input and analysis of EDCTP funded VITA 1 and 2 trials.
Collaborator Contribution Long standing nesting of key pharmacokinetic studies within larger trial programmes. Contributed to several PhD studentships (all Dutch), PK data resulted in licensing of new appropriate antiretroviral formulations for children in resource limited settings.
Impact Radbound University has been involved in the analysis and writing up of the pharmacokinetics data from ARROW, PENTA 18 and the CHAPAS trials which has resulted in presentations at international conferences, peer review publications, FDA and EMA approval of drugs and Clinton Foundation and UNITAID dissemination in Africa.
Start Year 2007
 
Description SGUL 
Organisation St George's University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution design and conduct of study protocol.
Collaborator Contribution SGUL - Chief Investigator and Trial Physician; PERUKI, Universities of Oxford/Bristol /UCL ICH- design and analysis of laboratory studies; University of Southampton Health Economics
Impact Multi-disciplinary - clinical, health economics, laboratory
Start Year 2013
 
Description The London School of Hygiene and Tropical Medicine 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Department Faculty of Public Health and Policy
Country United Kingdom 
Sector Academic/University 
PI Contribution coordination and facilitation of the Young Lives substudy in the ARROW trial, qualatative substudy of PENTA 16 (UK, Uganda and US) and input in to AALPHI.
Collaborator Contribution intensive training in areas of social science adding to collaborations in the African centres (ARROW and PENTA 16). provision of a forum for young people in the ARROW trial to contribute to knowledge about living with HIV infection in Africa
Impact 3 Social Scientists trained in Africa; publications and presentations at major conferences on qualitative work in ARROW and BREATHER (PENTA 11)
Start Year 2011
 
Description UZCRC, Zimbabwe 
Organisation University of Zimbabwe
Department University of Zimbabwe Clinical Research Centre
Country Zimbabwe 
Sector Academic/University 
PI Contribution MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis
Collaborator Contribution UZCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade.
Impact Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including DART, ARROW, EARNEST and REALITY trials. Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines.
 
Description University Teaching Hospital (UTH), Lusaka 
Organisation University Teaching Hospital
Country Zambia 
Sector Hospitals 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Description University of Cape Town 
Organisation University of Cape Town
Department Division of Clinical Pharmacology
Country South Africa 
Sector Academic/University 
PI Contribution MRC CTU coordinates the CHAPAS 3, PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials.
Collaborator Contribution Dr Helen McIlleron's team designed, coordinate and analyse pharmacokinetic studies in collaboration with Prof David Burger from Nimejgen. Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. Clinical site for PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials
Impact Analyses of CHAPAS 3 data are currently in progress
Start Year 2010
 
Description University of Zimbabwe Clinical Research Centre (UZCRC), Harare 
Organisation University of Zimbabwe
Department University of Zimbabwe Clinical Research Centre
Country Zimbabwe 
Sector Academic/University 
PI Contribution This is a recruiting site to the SURE study
Collaborator Contribution This is a recruiting site to the SURE study
Impact This is a recruiting site to the SURE study
Start Year 2019
 
Title CAP-IT - amoxicillin 
Description Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community Acquired Pneumonia (CAP): a randomIsed controlled Trial (CAP-IT). Funded by NIHR HTA. Recruitment started Q1 2017. Collaboration with PERUKI, SGUL, Universities of Bristol, Southampton, Oxford. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2016
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier HTA 13/88/11
Impact Feasibility study completed. Pilot study will include validation of saliva swabs against nasopharyngeal swabs for identification of S.pneumoniae and identification of changes in antibiotic resistance. 
URL http://www.isrctn.com/ISRCTN76888927
 
Title Enhanced opportunistic infection prophylaxis 
Description In the REALITY trial we tested a "bundle" of drugs as enhanced prophylaxis for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if the bundle reduces early mortality on treatment. The bundle contains isoniazid (anti-tuberculosis), fluconazole (anti-cryptococcus), azithromycin (anti-bacterial infections) and albendazole (anti-helminths). This reduced mortality after starting treatment by 25%, and has been included in WHO guidelines. It has recently been shown to be the most cost-effective of 6 different prophylaxis strategies for late presenting HIV patients. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2016
Development Status Under active development/distribution
Clinical Trial? Yes
Impact None 
URL http://www.isrctn.com/ISRCTN43622374
 
Title ODYSSEY - PENTA 20 
Description ODYSSEY (Once daily dolutegravir in young people vs standard therapy) - A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART. FPFV due April 2016. Funding from EU, PENTA Foundation, ViiV, INSERM. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Market authorisation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact n/a 
URL http://penta-id.org
 
Title Plumpynut 
Description Plumpynut is a nutritional supplement made from peanuts, and including specific multi-vitamins and multi-minerals. In the REALITY trial we tested using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduced early mortality on treatment. It did lead to greater weight gain, but did not impact mortality. It therefore should not be recommended at present as a way to reduce mortality in late HIV presenters. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2016
Development Status Closed
Clinical Trial? Yes
Impact None. 
URL http://www.isrctn.com/ISRCTN43622374
 
Title Raltegravir 
Description Raltegravir is an integrase inhibitor licenced for the treatment of HIV infection. In the REALITY trial we tested using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduced early mortality on treatment. Raltegravir did reduce HIV viral load much faster when combined with standard of care, but this did not lead to any improvements in mortality. Adjunctive raltegravir could be useful in women identified as infected during pregnancy (as it reduces viral load faster, hence reducing transmission risk to the unborn child) but does not have wider utility in HIV late presenters. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2016
Development Status Closed
Clinical Trial? Yes
Impact None. 
URL http://www.isrctn.com/ISRCTN43622374
 
Title elvitegravir 
Description A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact First patient expected Q2 2016 
URL http://www.penta-id.org
 
Description Anna Turkova: PADO-4: Paediatric ARV Drug Optimization 4 Meeting Invited talk: Treatment simplification strategies 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact World Health Organisation meeting, PADO-4 (Paediatric ARV Drug Optimization 4) meeting where Anna Turkova was invited to present 'Treatment simplification strategies.'

WHO recently convened Paediatric Antiretroviral Drug Optimization (PADO) Meeting 4 to take stock of the progress made and further advance the agenda for optimizing antiretroviral therapy for children. This meeting aimed to review the medium- and long-term priorities for drug and formulation development and to identify additional research gaps in this area. The meeting brought together researchers, clinicians, programme managers and other stakeholders and provided the opportunity to foster coordination and further develop collaborations to take the required actions for scaling up treatment for children and adolescents living with HIV.
Year(s) Of Engagement Activity 2018
 
Description Anna Turkova: The International Liver Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The International Liver Congress is the annual EASL meeting, and Anna Turkova was invited to speak at the EASL-WHO symposium, 'Promoting access to DAAs for children and adolescents and experience of use in pregnant women).'

Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research. The annual Congress attracts around 10,000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity!
Year(s) Of Engagement Activity 2019
 
Description Annual meeting of the Child and Adolescent TB working group: Update on SHINE trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Update on SHINE trial - a phase III randomised trial of treatment shortening in children with minimal TB disease presented at the annual WHO Child and Adolescent TB working group.
Year(s) Of Engagement Activity 2019
 
Description BREATHER (PENTA 16) results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of the results of the trial at a major scientific conference. Butler K on behalf of the BREATHER trial team: ART with weekends off is non-inferior to continuous ART in young people on EFV+2 NRTI. CROI 2015, Seattle, USA, Feb 23 -26 2015. Oral presentation abstract 38LB.
Year(s) Of Engagement Activity 2015
URL http://penta-id.org
 
Description BREATHER briefing paper 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact We produced a briefing paper on the BREATHER trial results.
Year(s) Of Engagement Activity 2016
URL http://www.ctu.mrc.ac.uk/13706/13710/breather_briefing_paper
 
Description Blog 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact I wrote a blog that has been published by the Centre for Maternal, Adolescent, Reproductive, & Child Health (MARCH) at the London School of Hygiene & Tropical Medicine exploring the growing population of children who are HIV-exposed but uninfected (https://www.lshtm.ac.uk/research/centres/march-centre/news/88751 or Short link: bit.ly/exposeduninfected). The blog has received over 140 visitors and has been publicised in the LSHTM and MARCH newsletters and sparked feedback, requests for further information and interest in the topic.
Year(s) Of Engagement Activity 2019
URL http://bit.ly/exposeduninfected
 
Description CAPIT Meta-Analysis Poster Presentation - RCPCH 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Meta-analysis poster displayed at the RCPCH 2019 conference summarising the findings from the meta-planning exercise results from the trial's investigator's meeting September 2018.
Year(s) Of Engagement Activity 2019
 
Description CHAPAS-4 stakeholder mapping and communication training workshops 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We ran four workshops for CHAPAS-4 partners, which covered stakeholder mapping, developing communications strategies, writing key messages, writing for non-scientific audiences and presenting to non-scientific audiences. The workshops were held in Zambia, Zimbabwe, and two in Uganda. Attendees reported that the training was very helpful. Based on the stakeholder mapping we have now developed the communications strategy for CHAPAS-4.
Year(s) Of Engagement Activity 2018,2019,2020
 
Description CHIVA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Twice yearly contribution of lay text on the CHIPS study to the CHIVA Newsletter; yearly presentation of key findings from the CHIPS and AALPHI studies at the CHIVA national conference. Updating on results and ongoing PENTA trials

Improved reporting of patients to CHIPS, and general understanding of the CHIPS data and its importance. Recruitment of patients into PENTA trials
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description CHIVA Annual Conference: Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker to the annual CHIVA conference in London.
Title of talk: PENTA - A global Update
Year(s) Of Engagement Activity 2019
URL https://www.chiva.org.uk/professionals/previous-conferences/2019-annual-chiva-conference/
 
Description CTU Seminar Series: Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact About 80 people attended the seminar which was highlighting the impact of the CHAPAS HIV trials that have been conducted from the CTU and led by Prof Gibb over the past 20 years. The seminar sparked questions around the future of the CHAPAS trials and the international collaborations.
Title of talk: Impact of the CHAPAS trials
Year(s) Of Engagement Activity 2019
 
Description ESPID Plenary Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact I as invited and gave the plenary lecture at ESPID (European Society for Paediatric Infectious Diseases) which is an international conference addressing clinicians and policymakers. The talk ws well recieved to an audience of over 100 and which discussed the trials run from CTU, SHINE/CHAMP/SURE/STREAM/REALITY/CAPIT/ODYSSEY/ARROW
Title of the talk: New ways of doing clinical trials in infectious diseases to maximise evidence generation
Year(s) Of Engagement Activity 2019
 
Description Invited speaker at PENTA HIV Training 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker at the international HIV paediatric training programme run by PENTA ID.
Title of talk; TB Research Update/Research and adolescents, trials and their involvement
Year(s) Of Engagement Activity 2019
 
Description Lablite training briefing paper 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We produced a briefing paper summarising the training approach used within Lablite. This briefing paper was distributed at the International AIDS Conference in Durban.
Year(s) Of Engagement Activity 2016
 
Description London Specialised Commissioning Group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Annual production of a newsletter (annual report) and slide set which presents CHIPS data in lay language. Presentation of data at twice yearly London HIV Consortium meetings

CHIPS data are now used as the basis for commissioning paediatric HIV services across England, and are being developed to measure quality of services within new designation schemes.
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description MRC Festival Workshop on Getting Results Faster for Patients 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact As part of the Medical Research Council (MRC) Festival of Medical Research, the MRC Clinical Trials Unit at University College London (MRC CTU at UCL) held a half-day workshop exploring how the Unit is working to get faster results and impact from clinical trials. We invited patient representatives involved in our studies, and patient groups who are interested in clinical trials. 30 people from 20 patient groups and various trials attended the workshop, along with around 20 members of MRC CTU at UCL staff.
Year(s) Of Engagement Activity 2016
URL http://www.ctu.mrc.ac.uk/news/2016/getting_results_faster_workshop_report_010816
 
Description Media Publications 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Results reported from the REALITY trial in Paris for the IAS conference on HIV science where published by the British media.
Year(s) Of Engagement Activity 2017
URL https://www.theguardian.com/global-development/2017/jul/24/cocktail-of-drugs-could-prevent-10000-hiv...
 
Description Meeting of paediatricians and blood transfusion services from across sub-Saharan Africa 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The TRACT trial team, in partnership with the African Society for Blood Transfusion and Uganda Paediatric Society, convened a meeting bringing together leading paediatricians and blood transfusion services from across sub-Saharan Africa, to discuss the results of the trial and what they mean for policy and practice. A treatment algorithm was developed at the meeting.
Year(s) Of Engagement Activity 2020
 
Description Presentation of BREATHER (PENTA 16) qualitative results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team. "But it's my story": exploring the experience and effect of telling children how they have acquired HIV; 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
Year(s) Of Engagement Activity 2015
URL http://penta-id.org
 
Description Presentation of BREATHER and ARROW qualitative work 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams 'I am scared of getting caught up in my lie': challenges to self-reported adherence for young people living with HIV; accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
Year(s) Of Engagement Activity 2015
URL http://penta-id.org
 
Description Presentation of further results of BREATHER (PENTA 16) qualitative work 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team. Young people, clinical trials and 'the HIV experience': What can similarities across time and place tell us about growing up with HIV? 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
Year(s) Of Engagement Activity 2015
URL http://penta-id.org
 
Description Presentation of qualitative work in BREATHER (PENTA 16 ) in the UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Bernays S, Seeley J, Paparini S, Rhodes T and the BREATHER trial teams 'I was like, oh my God, what happens if it doesn't work'?: young people living with HIV, clinical trial participation, and the truth economy accepted for presentation at BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148).
Year(s) Of Engagement Activity 2015
URL http://penta-id.org
 
Description Stand at International AIDS Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We had a stand at the International AIDS Conference in Durban, distributing outputs from our HIV studies including policy briefs, graphic novels, films and video case studies and other training materials.
Year(s) Of Engagement Activity 2016
 
Description TRACT 20mls vs 30mls animated abstract 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This animated abstract summarises the results of the TRACT trial in relation to the volume of blood children with severe anaemia require.
Year(s) Of Engagement Activity 2019
URL https://vimeo.com/344562147
 
Description TRACT briefing paper on 20mls vs 30mls transfusions 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact This briefing paper describes the results of the TRACT trial in relation to the volume required for blood transfusions for children with severe anaemia, and examines the implications for policy and practice.
Year(s) Of Engagement Activity 2019
URL https://www.ctu.mrc.ac.uk/media/1709/tract-20vs30mls-briefing-final-020819.pdf
 
Description TRACT film 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This film explores the results and implications of the TRACT trial.
Year(s) Of Engagement Activity 2019
URL https://vimeo.com/350115186
 
Description TRACT immediate vs no immediate transfusion animated abstract 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This short animation summarises the results of the TRACT trial in relation to whether children with uncomplicated severe anaemia require an immediate transfusion.
Year(s) Of Engagement Activity 2019
URL https://vimeo.com/344562242
 
Description TRACT immediate vs no immediate transfusion briefing paper 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact This briefing paper describes the results of the TRACT trial in relation to immediate vs no immediate transfusion for children with uncomplicated severe anaemia, and examines the implications for policy and practice.
Year(s) Of Engagement Activity 2019
URL https://www.ctu.mrc.ac.uk/media/1710/tract-immediate-vs-no-immediate-transfusion-briefing-final-0208...
 
Description TRACT immediate vs no immediate transfusion infographic 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This infographic summarises the results of the TRACT trial in terms of immediate vs no immediate transfusion for children with uncomplicated severe anaemia.
Year(s) Of Engagement Activity 2019
URL https://www.ctu.mrc.ac.uk/media/1707/full-infographic-immediate-vs-no-immediate-transfusion-020819.p...
 
Description TRACT transfusion volume infographic 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This infographic summarises the results of the TRACT trial in relation to the volume of blood required for transfusion for children with severe anaemia.
Year(s) Of Engagement Activity 2019
URL https://www.ctu.mrc.ac.uk/media/1708/full-infographic-transfusion-volume-020819.png
 
Description Youth Trial Board meeting with MRC CTU 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact We held a meeting with the UK Youth Trial Board to share our research and get their feedback.
Year(s) Of Engagement Activity 2017